Association Between Antipsychotic Use and Risk of Acute Myocardial Infarction
| Autor: | Shuai-Ting Lin, Yung-Chi Hsieh, Wei-Cheng Yang, Chin-Jen Wang, Chee-Siong Lee, Kai Da Cheng, Pinchen Yang, Cheng-Chung Chen, Hin-Yeung Tsang, Dian-Jeng Li |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.medical_treatment Myocardial Infarction Taiwan Young Adult Sex Factors Risk Factors Physiology (medical) Internal medicine medicine Humans Myocardial infarction Antipsychotic Psychiatry Aged Retrospective Studies Aged 80 and over Cross-Over Studies Dose-Response Relationship Drug business.industry Incidence Incidence (epidemiology) Age Factors Odds ratio Middle Aged medicine.disease Crossover study Confidence interval Mood disorders Schizophrenia Female Cardiology and Cardiovascular Medicine business Antipsychotic Agents |
| Zdroj: | Circulation. 130:235-243 |
| ISSN: | 1524-4539 0009-7322 |
| DOI: | 10.1161/circulationaha.114.008779 |
| Popis: | Background— Antipsychotic medications have been increasingly and more widely prescribed despite continued uncertainty about their association with the incidence of acute myocardial infarction (AMI). Methods and Results— We investigated the risk of AMI associated with antipsychotic treatment in 56 910 patients with schizophrenia, mood disorders, or dementia first hospitalized or visiting an emergency room for AMI in 1999 to 2009. A case-crossover design was used to compare the distributions of antipsychotic exposure for the same patient across 1 to 30 and 91 to 120 days just before the AMI event. Adjustments were made for comedications and outpatient visits. The adjusted odds ratio of AMI risk was 2.52 (95% confidence interval, 2.37–2.68) for any antipsychotics, 2.32 (95% confidence interval, 2.17–2.47) for first-generation antipsychotics, and 2.74 (95% confidence interval, 2.49–3.02) for second-generation antipsychotics. The risk significantly increased ( P P P P P Conclusions— Antipsychotic use may be associated with a transient increase in risk for AMI, possibly mediated by dopamine type 3 receptor blockades. Further education on drug safety and research into the underlying biological mechanisms are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|